Sarepta ’s Duchenne gene therapy fails to meet main goal in key trial
The Cambridge biotech said late Monday that its gene therapy to treat Duchenne muscular dystrophy failed to meet the primary goal of a large Phase 3 trial, but that it plans to seek full approval regardless.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Health Management | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy